Iberdomide (Zenbexus) for multiple myeloma.
Unknown authors
Medicine
Abstract
Iberdomide (Zenbexus – BMS), an oral first-in-class cereblon-modulating protein degrader, has received accelerated approval from the FDA for use in combination with the CD38-directed cytolytic antibody daratumumab (Darzalex Faspro) and dexamethasone for treatment of multiple myeloma in adults who received at least one prior line of therapy, including a proteasome inhibitor (e.g., bortezomib) and an immunomodulatory drug. The drug was approved based on a surrogate endpoint of minimal residual disease-negative complete response.